# US 12,005,070 B2 · Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,070 B2
- Document ID: US12005070B2
- Status: Granted
- Kind: B2
- Application number: 15/254,655
- Filed: 2016-09-01
- Published: 2016-12-22
- Granted: 2024-06-11
- Earliest claimed: 2011-11-24
- Assignees: Toyo Sugar Refining Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.
- Applicants: Toyo Sugar Refining Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.
- Inventors: Kyo Aizawa; Yoshihisa Iida; Takashi Shimoida; Yasuhiro Kotani; Koushi Iwata; Kazuhisa Doi
- Web page: https://patentgrep.com/patent/US12005070B2

## CPC

- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol.

## Claims

### Claim 1

A method of protecting keratoconjunctiva from dry eye in a subject, the method comprising: administering to the subject's eye an ophthalmic formulation comprising an effective amount of glucosylglycerol and an ophthalmically acceptable carrier, wherein the glucosylglycerol is present in an amount of from 0.01 to 10% by mass of the ophthalmic formulation.

### Claim 2 (depends on 1)

The method of claim 1 wherein the glucosylglycerol is 1-α-glyceryl glucoside, 2-α-glyceryl glucoside, 1-β-glyceryl glucoside, 2-β-glyceryl glucoside or a mixture thereof.

### Claim 3

A method for treating dry eye in a subject, the method comprising: administering to the subject's eye an ophthalmic formulation comprising an effective amount of glucosylglycerol and an ophthalmically acceptable carrier, wherein the glucosylglycerol is present in an amount of from 0.01 to 10% by mass of the ophthalmic formulation.

### Claim 4 (depends on 3)

The method of claim 3 wherein the glucosylglycerol is 1-α-glyceryl glucoside, 2-α-glyceryl glucoside, 1-β-glyceryl glucoside, 2-β-glyceryl glucoside or a mixture thereof.